ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Catalent has acquired a cell therapy facility in Princeton, New Jersey, from Erytech Pharma for $44.5 million. Catalent says it will supply Erytech with eryaspase, a red blood cell–derived leukemia treatment that Erytech is developing. The drug services firm will also lease nearby buildings for possible expansion. Separately, South Korea’s GC will acquire BioCentriq, which provides services to cell and gene therapy companies. GC says it plans an expansion adjacent to BioCentriq’s facility in Newark, New Jersey.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter